FIZE Medical Ltd.

Based in Modi’in, Israel, and founded in 2014, by founder Noam Levine (CTO), FIZE Medical Inc. , develops solutions for monitoring vital signs using urine. The platform monitors a patient’s renal function to determine their hemodynamic state. In March 2026, FIZE Medical Ltd.

raised USD 6 million in series A funding. FIZE offers various medical devices, such as iUO, iUO PLUS, iUO DUOFLO, FIZE kUO PLUS, and FIZE dUO, that allow nursing and nursing aide staff to measure and record urine output and send automatic warnings to doctors and residents when the catheter becomes clogged or when urine production falls below particular trigger levels. These devices also improve the early diagnosis and treatment of acute kidney injury (AKI), sepsis, and other critical events that require early detection to achieve the best outcomes for patients. In addition to urine outflow management, the company offers advanced non-invasive, real-time urinalysis, hematuria and infection monitoring, and fluid inflow management.

The company will use the March 2026 funding to accelerate commercial adoption in Japan, Europe, and the United States, advance research and development, and expand clinical validation studies.